Chronic type IV phosphodiesterase inhibition protects glomerular filtration rate and renal and mesenteric blood flow in a zymosan-induced model of multiple organ dysfunction syndrome treated with norepinephrine

Journal of Pharmacology and Experimental Therapeutics

Volumn 296, Issue 1, 2001, Pages 168-174

  Thomas, Neal J ^a,b   Carcillo, Joseph A ^a   Herzer, William A ^a   Mi, Zaichuan ^a   Jackson, Edwin K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; CATECHOLAMINE; CYCLIC AMP; NORADRENALIN; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; HEART RATE; INFUSION PUMP; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; MESENTERY BLOOD FLOW; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAT; SUPERIOR MESENTERIC ARTERY; VASCULAR RESISTANCE; VASOCONSTRICTION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; 4-(3-BUTOXY-4-METHOXYBENZYL)-2-IMIDAZOLIDINONE; ADRENERGIC ALPHA-AGONISTS; ANIMALS; BLOOD PRESSURE; CYCLIC AMP; GLOMERULAR FILTRATION RATE; HEART RATE; HEMODYNAMIC PROCESSES; MALE; MULTIPLE ORGAN FAILURE; NOREPINEPHRINE; PHOSPHODIESTERASE INHIBITORS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RENAL CIRCULATION; SPLANCHNIC CIRCULATION; VASCULAR RESISTANCE; ZYMOSAN;

EID: 0035197164     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. The impact of antioxidant and splanchnic-directed therapy on persistent uncorrected gastric mucosal pH in the critically injured trauma patient
2. Inhibition of type IV phosphodiesterase by Ro 20-1724 attenuates endotoxin-induced acute renal failure
3. Modulation of inflammation and immunity by cyclic AMP
4. Treatment with the type IV phosphodiesterase inhibitor Ro 20-1724 protects renal and mesenteric blood flow in endotoxemic rats treated with norepinephrine
5. Multiple-organ-failure syndrome
6. Formation of reactive oxygen metabolites in glomeruli is suppressed by inhibition of cAMP phosphodiesterase isozyme type IV
7. The role of intestinal barrier failure and bacterial translocation in the development of systemic infection and multiple organ failure
8. Alterations in the functions of the reticuloendothelial and protease-antiprotease systems after intraperitoneal injection of zymosan in rats
9. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibition of type IV phosphodiesterase: Interaction with beta adrenoceptor agonist albuterol
10. Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney
11. Interleukin-10 reduces morbidity and mortality in murine multiple organ dysfunction syndrome (MODS)
12. Protection by phosphodiesterase inhibitors against endotoxin-induced liver injury in galactosamine-sensitized mice
13. Deterioration of renal function during hyperdynamic endotoxaemia correlates with re-distribution of intrarenal blood flow
14. Multiple organ failure and sepsis without bacteria: An experimental model
15. The effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines
16. Phosphodiesterases in the rat renal vasculature
17. Gradual development of organ damage in the murine zymosan-induced multiple organ dysfunction syndrome
18. Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome
19. Chlorpromazine down-regulates tumor necrosis factor-alpha and attenuates experimental multiple organ dysfunction syndrome in mice
20. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-α and IL-6 release by endotoxin-stimulated macrophages
21. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response
22. Splanchnic ischaemia and its role in multiple organ failure
23. The PDE IV family of calcium-independent phosphodiesterase enzymes
24. Organ damage is preceded by changes in protein extravasation in an experimental model of multiple organ dysfunction syndrome
25. Relationships among endotexemia, arterial pressure and renal function in dogs
26. Splanchnic ischemia and gut mucosal injury in sepsis and the multiple organ dysfunction syndrome
27. Prolonged changes in protein and amino acid metabolism after zymosan treatment in rats
28. Decreased mesenteric blood flow in experimental multiple organ failure
29. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation
30. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells
31. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer
32. Development of a bacteria-independent model of the multiple organ failure syndrome
33. Renal function and metabolism during endotoxemia in rats: Role of hypoperfusion
34. Differential regulation of human monocyte-derived TNFα and IL-1β by type IV cAMP-phosphodiesterase inhibitors
35. Plasma endothelin levels are increased during septic shock
36. Acute renal failure and multiorgan failure